graphites akh c98-c229-c999 tableta
akademie klasické homeopatie, spol. s r.o., ostrava array - 51982 graphites 98 c; 51984 graphites 229 c; 51900 graphites 999 c - tableta - c98-c229-c999 - homeopatika (ČeskÁ atc skupina)
agraphis nutans 2ch-200ch granule
boiron, messimy array - 51127 agraphis nutans - dilutio homeopathica - granule - 2ch-200ch - homeopatika (ČeskÁ atc skupina)
graphites 3ch-200ch granule
boiron, messimy array - 50550 graphites - dilutio homeopathica - granule - 3ch-200ch - homeopatika (ČeskÁ atc skupina)
ade-vit injekční roztok
bioveta, a.s. - kombinace vitamínů - injekční roztok - other vitamin products, combinations - skot, koně, prasata, ovce, kozy, psi, králíci
calcium 20 % injekční roztok
bb pharma a.s. - vápník (různé soli v kombinaci) - injekční roztok - 20% - vápník - skot, koně, prasata, psi, drůbež
calfoset injekční roztok
krka d.d. novo mesto - vápník, kombinace s vitaminem d a / nebo jinými léky - injekční roztok - vÁpnÍk - koně, skot, ovce, kozy, prasata
fosfovet forte injekční roztok
pharmagal s.r.o. - jiné minerální produkty, kombinace - injekční roztok - jiné minerální produkty - prasata, skot
triavit injekční roztok
pharmagal s.r.o. - kombinace vitamínů - injekční roztok - other vitamin products, combinations - koně, ovce, prasata, psi, skot, králíci, drůbež
fosfovet forte 100 mg/ml injekční roztok
pharmagal s.r.o. - jiné minerální produkty, kombinace - injekční roztok - jiné minerální produkty - prasata, skot
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - artritida, revmatoidní - imunosupresiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.